BG106149A - Съвместни пролекарствени средства на амлодипин и аторвастатин - Google Patents

Съвместни пролекарствени средства на амлодипин и аторвастатин

Info

Publication number
BG106149A
BG106149A BG106149A BG10614901A BG106149A BG 106149 A BG106149 A BG 106149A BG 106149 A BG106149 A BG 106149A BG 10614901 A BG10614901 A BG 10614901A BG 106149 A BG106149 A BG 106149A
Authority
BG
Bulgaria
Prior art keywords
atorvastatin
amlodipin
joint
mammals
methods
Prior art date
Application number
BG106149A
Other languages
Bulgarian (bg)
English (en)
Inventor
George Chang
Ernest Hamanaka
John LAMATTINA
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106149A publication Critical patent/BG106149A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BG106149A 1999-05-27 2001-11-26 Съвместни пролекарствени средства на амлодипин и аторвастатин BG106149A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27
PCT/IB2000/000313 WO2000073298A1 (en) 1999-05-27 2000-03-20 Mutual prodrugs of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
BG106149A true BG106149A (bg) 2002-05-31

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106149A BG106149A (bg) 1999-05-27 2001-11-26 Съвместни пролекарствени средства на амлодипин и аторвастатин

Country Status (41)

Country Link
US (1) US6486182B1 (is)
EP (1) EP1180102B9 (is)
JP (1) JP2003500487A (is)
KR (1) KR20020012247A (is)
CN (1) CN1352640A (is)
AP (1) AP2001002345A0 (is)
AR (1) AR022344A1 (is)
AT (1) ATE268764T1 (is)
AU (1) AU3313900A (is)
BG (1) BG106149A (is)
BR (1) BR0011006A (is)
CA (1) CA2375372C (is)
CO (1) CO5170457A1 (is)
CZ (1) CZ20014229A3 (is)
DE (1) DE60011424T2 (is)
DK (1) DK1180102T3 (is)
DZ (1) DZ3048A1 (is)
EA (1) EA200101130A1 (is)
EE (1) EE200100631A (is)
ES (1) ES2220426T3 (is)
GT (1) GT200000078A (is)
HK (1) HK1046282A1 (is)
HN (1) HN2000000075A (is)
HR (1) HRP20010856A2 (is)
HU (1) HUP0201433A2 (is)
IL (1) IL145947A0 (is)
IS (1) IS6135A (is)
MA (1) MA26736A1 (is)
MX (1) MXPA01012125A (is)
NO (1) NO20015756L (is)
OA (1) OA11950A (is)
PA (1) PA8495701A1 (is)
PE (1) PE20010169A1 (is)
PL (1) PL353483A1 (is)
PT (1) PT1180102E (is)
SK (1) SK16792001A3 (is)
SV (1) SV2002000082A (is)
TN (1) TNSN00113A1 (is)
TR (1) TR200103391T2 (is)
WO (1) WO2000073298A1 (is)
ZA (1) ZA200109691B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
EP1909848A2 (en) * 2005-08-01 2008-04-16 PSivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8371336B2 (en) 2007-10-10 2013-02-12 Eagle Industry Co., Ltd. Accumulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
ATE268764T1 (de) 2004-06-15
CA2375372A1 (en) 2000-12-07
DZ3048A1 (fr) 2004-03-27
MXPA01012125A (es) 2002-06-04
ZA200109691B (en) 2002-11-26
DE60011424D1 (de) 2004-07-15
BR0011006A (pt) 2002-02-19
IS6135A (is) 2001-10-30
HN2000000075A (es) 2001-02-02
CO5170457A1 (es) 2002-06-27
AR022344A1 (es) 2002-09-04
CA2375372C (en) 2007-01-09
PL353483A1 (en) 2003-11-17
EP1180102B1 (en) 2004-06-09
EP1180102B9 (en) 2005-03-02
WO2000073298A1 (en) 2000-12-07
MA26736A1 (fr) 2004-12-20
EA200101130A1 (ru) 2002-04-25
PA8495701A1 (es) 2001-12-14
ES2220426T3 (es) 2004-12-16
TR200103391T2 (tr) 2002-04-22
CN1352640A (zh) 2002-06-05
SK16792001A3 (sk) 2003-03-04
JP2003500487A (ja) 2003-01-07
NO20015756L (no) 2002-01-24
DK1180102T3 (da) 2004-09-06
EE200100631A (et) 2003-02-17
PT1180102E (pt) 2004-08-31
HRP20010856A2 (en) 2002-12-31
KR20020012247A (ko) 2002-02-15
PE20010169A1 (es) 2001-02-10
HUP0201433A2 (en) 2002-08-28
DE60011424T2 (de) 2005-08-25
HK1046282A1 (zh) 2003-01-03
AP2001002345A0 (en) 2001-12-31
AU3313900A (en) 2000-12-18
EP1180102A1 (en) 2002-02-20
SV2002000082A (es) 2002-02-05
IL145947A0 (en) 2002-07-25
CZ20014229A3 (cs) 2003-01-15
OA11950A (en) 2006-04-13
TNSN00113A1 (fr) 2005-11-10
US6486182B1 (en) 2002-11-26
NO20015756D0 (no) 2001-11-26
GT200000078A (es) 2001-11-16

Similar Documents

Publication Publication Date Title
BG106128A (bg) Обща сол на aмлодипин и аторвастатин
CY1105108T1 (el) Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη
AP1745A (en) Pharmaceutical compositions of amlodipine and atorvastatin.
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
EA200101130A1 (ru) Общие пролекарства амлодипина и аторвастатина
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
EA200100702A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
EA200301223A1 (ru) Лекарственные формы окскарбазепина
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
ECSP003493A (es) Profarmacos mutuos de amlodipino y atorvastatina
CY1105302T1 (el) Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης
ATE253565T1 (de) Inhibitoren der cholesterolesterase
UY26164A1 (es) Profarmácos mutuos de amlodipino y atorvastatina
ECSP003497A (es) Sal mutua de amlodipino y atorvastatina